Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report
High efficacy of anti-PD-1 therapy has been shown in malignant tumors with mismatch repair deficiency. According to the literature review, mismatch repair deficiency is determined in 20–40 % of all endometrial cancer cases and up to 48 % of its endometrioid subtype. We report the short review of the...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2019-07-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/636 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839570937065766912 |
|---|---|
| author | T. T. Andabekov M. K. Rodina G. A. Raskin K. G. Cham I. O. Rutkin |
| author_facet | T. T. Andabekov M. K. Rodina G. A. Raskin K. G. Cham I. O. Rutkin |
| author_sort | T. T. Andabekov |
| collection | DOAJ |
| description | High efficacy of anti-PD-1 therapy has been shown in malignant tumors with mismatch repair deficiency. According to the literature review, mismatch repair deficiency is determined in 20–40 % of all endometrial cancer cases and up to 48 % of its endometrioid subtype. We report the short review of the recent literature and the case of durable partial response on pembrolizumab immunotherapy in a patient with a metastatic endometrioid adenocarcinoma with MMR-deficiency progressed on 2 chemotherapy lines. Partial response was achieved after 6th course, treatment was stopped after 8th course. Patient is on follow-up without any anticancer treatment for 11 months. Partial response lasts for 13 months, with further reduction in tumor size. The treatment was well tolerated without adverse events. |
| format | Article |
| id | doaj-art-a348c7f5ea9d4a4281f92fd527f8ffb7 |
| institution | Matheson Library |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| publishDate | 2019-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj-art-a348c7f5ea9d4a4281f92fd527f8ffb72025-08-04T14:33:40ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272019-07-01151737710.17650/1994-4098-2019-15-1-73-77607Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case reportT. T. Andabekov0M. K. Rodina1G. A. Raskin2K. G. Cham3I. O. Rutkin4LLC “AV medical group”LLC “AV medical group”A.M. Granov Russian Research Center of Radiology and Surgical Technologies, Ministry of Health of Russia; Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia; Saint Petersburg State UniversityA.M. Granov Russian Research Center of Radiology and Surgical Technologies, Ministry of Health of RussiaA.M. Granov Russian Research Center of Radiology and Surgical Technologies, Ministry of Health of RussiaHigh efficacy of anti-PD-1 therapy has been shown in malignant tumors with mismatch repair deficiency. According to the literature review, mismatch repair deficiency is determined in 20–40 % of all endometrial cancer cases and up to 48 % of its endometrioid subtype. We report the short review of the recent literature and the case of durable partial response on pembrolizumab immunotherapy in a patient with a metastatic endometrioid adenocarcinoma with MMR-deficiency progressed on 2 chemotherapy lines. Partial response was achieved after 6th course, treatment was stopped after 8th course. Patient is on follow-up without any anticancer treatment for 11 months. Partial response lasts for 13 months, with further reduction in tumor size. The treatment was well tolerated without adverse events.https://ojrs.abvpress.ru/ojrs/article/view/636endometriоid adenocarcinomaendometrial carcinomadmmrmsi-himmunotherapypd-1 inhibitorpembrolizumab |
| spellingShingle | T. T. Andabekov M. K. Rodina G. A. Raskin K. G. Cham I. O. Rutkin Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report Опухоли женской репродуктивной системы endometriоid adenocarcinoma endometrial carcinoma dmmr msi-h immunotherapy pd-1 inhibitor pembrolizumab |
| title | Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report |
| title_full | Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report |
| title_fullStr | Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report |
| title_full_unstemmed | Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report |
| title_short | Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report |
| title_sort | successful anti pd 1 therapy in metastatic endometrial cancer with microsatellite instability a case report |
| topic | endometriоid adenocarcinoma endometrial carcinoma dmmr msi-h immunotherapy pd-1 inhibitor pembrolizumab |
| url | https://ojrs.abvpress.ru/ojrs/article/view/636 |
| work_keys_str_mv | AT ttandabekov successfulantipd1therapyinmetastaticendometrialcancerwithmicrosatelliteinstabilityacasereport AT mkrodina successfulantipd1therapyinmetastaticendometrialcancerwithmicrosatelliteinstabilityacasereport AT garaskin successfulantipd1therapyinmetastaticendometrialcancerwithmicrosatelliteinstabilityacasereport AT kgcham successfulantipd1therapyinmetastaticendometrialcancerwithmicrosatelliteinstabilityacasereport AT iorutkin successfulantipd1therapyinmetastaticendometrialcancerwithmicrosatelliteinstabilityacasereport |